Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons

Michael Karsy; Jian Guan; Adam Cohen; Howard Colman; Randy L Jensen

doi:10.1016/j.nec.2015.11.002

Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons

Neurosurg Clin N Am. 2016 Apr;27(2):249-60. doi: 10.1016/j.nec.2015.11.002. Epub 2016 Feb 18.

Authors

Michael Karsy¹, Jian Guan¹, Adam Cohen², Howard Colman³, Randy L Jensen⁴

Affiliations

¹ Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, 175 N. Medical Drive East, Salt Lake City, UT 84132, USA.
² Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA.
³ Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, 175 N. Medical Drive East, Salt Lake City, UT 84132, USA; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA.
⁴ Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, 175 N. Medical Drive East, Salt Lake City, UT 84132, USA; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA; Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA. Electronic address: randy.jensen@hsc.utah.edu.

PMID: 27012389
DOI: 10.1016/j.nec.2015.11.002

Abstract

Meningiomas are benign tumors of the central nervous system, with low recurrence risk for World Health Organization (WHO) grade I lesions but a high risk for WHO grade II and III lesions. Current standard treatments include maximum safe surgical resection when indicated and radiation. Only three systemic therapies alpha-interferon, somatostatin receptor agonists, and vascular endothelial growth factor inhibitors are currently recommended by the National Comprehensive Cancer Network for treatment of recurrent meningioma. This paper aims to review medical approaches in the treatment of meningiomas.

Keywords: Genetics; Medical management; Meningiomas; Targeted treatment.

Publication types

Review

MeSH terms

Combined Modality Therapy
Humans
Hydroxyurea / therapeutic use
Meningeal Neoplasms / drug therapy*
Meningeal Neoplasms / genetics
Meningeal Neoplasms / therapy
Meningioma / drug therapy*
Meningioma / genetics
Meningioma / therapy
Mutation
Neovascularization, Pathologic / drug therapy
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
Somatostatin / analogs & derivatives
Somatostatin / therapeutic use
Treatment Failure

Substances

Somatostatin
Receptor Protein-Tyrosine Kinases
Hydroxyurea